CrystalPharmaceuticals的发行价为每股45.95美元

2026-01-07 13:14

Crinetics Pharmaceuticals (CRNX) priced an underwritten public offering of 7.62M shares at a price to the public of $45.95 per share.
The gross proceeds to Crinetics from the offering are expected to be approximately $350M.
The underwriters have a 30-day option to purchase up to an additional 1.14M shares.
The offering is expected to close on or about January 8, 2026.
Net proceeds from the offering, together with its cash, cash equivalents and investment securities will be used to fund its commercial activities in connection with the launch of PALSONIFY, research and development of its product candidates, other research programs and other general corporate purposes.
The company may also use a portion of the remaining net proceeds to in-license, acquire, or invest in complementary businesses, technologies, products or assets; however, it has no current commitments or obligations to do so.
The stock price traded 1.4% higher on Tuesday during after-market hours of trading.

More on Crinetics Pharmaceuticals